Title | Data |
|---|---|
ISIN | DE000STRA555 |
WKN | STRA55 |
Symbol | SBS |
Reuters Intrument Code | SBSG.DE |
Bloomberg Instrument Code | SBS:GR |
Segment | Prime Standard |
Market | Regulated Market |
Type | Common Shares |
Form | Registered Shares |
Sector | Pharma & Healthcare |
Subsector | Medical Technology |
Registered capital | 12,157,841 Euro |
No. of shares | 12,157,841 |
Initial listing | August 25, 1998 |
Designated exchanges | Xetra; Frankfurt am Main |
Designated Sponsor | Hauck & Aufhäuser Privatbankiers AG |
Related indices | SDAX |
Accounting standard | IFRS |
End of financial year | December 31 |
2023 | 2022 | 2021 | 2020 | 2019 | ||
|---|---|---|---|---|---|---|
Annual low (Xetra) | EUR | 36.00 | 72.70 | 100.40 | 46.40 | 49.30 |
Annual high (Xetra) | EUR | 93.00 | 138.60 | 147.40 | 144.60 | 77.60 |
Closing price (Xetra) | EUR | 45.55 | 81.10 | 137.80 | 122.80 | 61.00 |
Annual performance excluding dividend | % | -43.8 | -41.1 | +12.2 | +101.3 | +21.3 |
Average trading volume per trading day | EUR | 555,652 | 1,240,704 | 1,489,029 | 2,217,521 | 326,410 |
Number of shares | Mio. shares | 12.2 | 12.2 | 12.1 | 12.1 | 12.0 |
Market capitalization | Mio. EUR | 553.8 | 986.0 | 1671.2 | 1486.2 | 733.8 |
Dividend per share | EUR | 0.55 | 0.97 | 0.95 | 0.90 | 0.84 |
Total dividend distribution | Mio. EUR | 6.7 | 11.8 | 11.5 | 10.9 | 10.1 |
Dividend yield | % | 1.2 | 1.2 | 0.7 | 0.7 | 1.4 |
STRATEC has a broad share ownership structure. Free float shares account for 59.62% and are held by numerous international and national investors. 40.38% of the shares are in fixed ownership. Of these, 0.02% are treasury stock held by STRATEC itself.
40.36% of the shares are attributable to the company's founder, Hermann Leistner, and to his family and investment companies.
Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG) shareholders and individuals having access to voting rights are obliged to notify the issuer and the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) immediately when reaching, exceeding or falling below the thresholds of 3 %, 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 50 % or 75 % of the voting rights in a publicly listed company either through the acquisition or disposal of shares or other financial instruments or by any other means (§§ 33, 38 and 39 WpHG). The issuer is obliged to release any notification of voting rights without delay.
We kindly request that any shareholders obliged to inform STRATEC SE about changes in voting right shares send a relevant notification by e-mail to the Investor Relations department (e-mail address: ir[at]stratec.com).
STRATEC has received the following notifications of voting rights:
| Date | Title |
|---|---|
| 10/29/2024 | Union Investment Privatfonds GmbH, Germany |
- 2025
- 2024
Date Title 10/29/2024 Union Investment Privatfonds GmbH, Germany - 2023
- 2022
- 2021no content available.
The following institutions analyze STRATEC SE on a regular basis:
| INSTITUTE | ANALYSTS | PHONE |
|---|---|---|
| Berenberg Bank | Odysseas Manesiotis | +44 20 37533200 |
| Deutsche Bank | Jan Koch | +49 69 91047428 |
| DZ Bank | Sven Kürten | +49 69 744792072 |
| Hauck Aufhäuser Investment Banking | Alexander Galitsa | +49 40 414388583 |
| Kepler Cheuvreux | Oliver Reinberg | +49 69 75696140 |
| Metzler Capital Markets | Alexander Neuberger | +49 69 21044366 |
| mwb research | Harald Hof | +49 40 30929358 |
| ODDO BHF | Oliver Metzger | +49 69 7183045 |
| Warburg Research | Michael Heider | +49 40 309537280 |
For various practical reasons, we are unable to provide all research reports available on the market. To ensure equal treatment and avoid highlighting any individual report, we do not publish any research reports on this website. We apologize for any inconvenience this might cause. However, the relevant information is generally available on finance portals on the internet.
Please note that STRATEC SE has no influence whatsoever on the opinions, assessments, or forecasts issued by the aforementioned institutions or their employees with regard to STRATEC SE or its performance. These are merely provided for information purposes, do not represent the opinion, assessment, or forecast of STRATEC SE, and are solely the responsibility of the aforementioned institutions or their employees.
Reference to these institutions in no way constitutes any confirmation or approval of the contents of the analyses compiled by these institutions or their employees. This list should under no circumstances be viewed as representing a request or solicitation to buy, sell, or hold shares in STRATEC SE, or as representing any other recommendation relevant to investment decisions.
- STOCK CHART
- BASIC DATA
Title
Data
ISIN
DE000STRA555
WKN
STRA55
Symbol
SBS
Reuters Intrument Code
SBSG.DE
Bloomberg Instrument Code
SBS:GR
Segment
Prime Standard
Market
Regulated Market
Type
Common Shares
Form
Registered Shares
Sector
Pharma & Healthcare
Subsector
Medical Technology
Registered capital
12,157,841 Euro
No. of shares
12,157,841
Initial listing
August 25, 1998
Designated exchanges
Xetra; Frankfurt am Main
and other regional exchanges in GermanyDesignated Sponsor
Hauck & Aufhäuser Privatbankiers AG
Related indices
SDAX
CDAX
Prime All Share
DAXsubsector Medical TechnologyAccounting standard
IFRS
End of financial year
December 31
- KEY FIGURES
2023
2022
2021
2020
2019
Annual low (Xetra)
EUR
36.00
72.70
100.40
46.40
49.30
Annual high (Xetra)
EUR
93.00
138.60
147.40
144.60
77.60
Closing price (Xetra)
EUR
45.55
81.10
137.80
122.80
61.00
Annual performance excluding dividend
%
-43.8
-41.1
+12.2
+101.3
+21.3
Average trading volume per trading day
EUR
Shares555,652
9,9161,240,704
12,2601,489,029
12,0412,217,521
22,615326,410
5,124Number of shares
Mio. shares
12.2
12.2
12.1
12.1
12.0
Market capitalization
Mio. EUR
553.8
986.0
1671.2
1486.2
733.8
Dividend per share
EUR
0.55
0.97
0.95
0.90
0.84
Total dividend distribution
Mio. EUR
6.7
11.8
11.5
10.9
10.1
Dividend yield
%
1.2
1.2
0.7
0.7
1.4
- SHAREHOLDER STRUCTURE
STRATEC has a broad share ownership structure. Free float shares account for 59.62% and are held by numerous international and national investors. 40.38% of the shares are in fixed ownership. Of these, 0.02% are treasury stock held by STRATEC itself.
40.36% of the shares are attributable to the company's founder, Hermann Leistner, and to his family and investment companies. - VOTING RIGHTS
- 2025
- 2024
Date Title 10/29/2024 Union Investment Privatfonds GmbH, Germany - 2023
- 2022
- 2021no content available.
Under the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG) shareholders and individuals having access to voting rights are obliged to notify the issuer and the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) immediately when reaching, exceeding or falling below the thresholds of 3 %, 5 %, 10 %, 15 %, 20 %, 25 %, 30 %, 50 % or 75 % of the voting rights in a publicly listed company either through the acquisition or disposal of shares or other financial instruments or by any other means (§§ 33, 38 and 39 WpHG). The issuer is obliged to release any notification of voting rights without delay.
We kindly request that any shareholders obliged to inform STRATEC SE about changes in voting right shares send a relevant notification by e-mail to the Investor Relations department (e-mail address: ir[at]stratec.com).
STRATEC has received the following notifications of voting rights:
20252024202320222021Date Title 10/29/2024 Union Investment Privatfonds GmbH, Germany no content available. - 2025
- ANALYSTS
The following institutions analyze STRATEC SE on a regular basis:
INSTITUTE ANALYSTS PHONE Berenberg Bank Odysseas Manesiotis +44 20 37533200 Deutsche Bank Jan Koch +49 69 91047428 DZ Bank Sven Kürten +49 69 744792072 Hauck Aufhäuser Investment Banking Alexander Galitsa +49 40 414388583 Kepler Cheuvreux Oliver Reinberg +49 69 75696140 Metzler Capital Markets Alexander Neuberger +49 69 21044366 mwb research Harald Hof +49 40 30929358 ODDO BHF Oliver Metzger +49 69 7183045 Warburg Research Michael Heider +49 40 309537280 For various practical reasons, we are unable to provide all research reports available on the market. To ensure equal treatment and avoid highlighting any individual report, we do not publish any research reports on this website. We apologize for any inconvenience this might cause. However, the relevant information is generally available on finance portals on the internet.
Please note that STRATEC SE has no influence whatsoever on the opinions, assessments, or forecasts issued by the aforementioned institutions or their employees with regard to STRATEC SE or its performance. These are merely provided for information purposes, do not represent the opinion, assessment, or forecast of STRATEC SE, and are solely the responsibility of the aforementioned institutions or their employees.
Reference to these institutions in no way constitutes any confirmation or approval of the contents of the analyses compiled by these institutions or their employees. This list should under no circumstances be viewed as representing a request or solicitation to buy, sell, or hold shares in STRATEC SE, or as representing any other recommendation relevant to investment decisions.
